Annovis Bio, Inc.
General ticker "ANVS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $32.7M (TTM average)
Annovis Bio, Inc. follows the US Stock Market performance with the rate: 19.9%.
Estimated limits based on current volatility of 6.4%: low 4.36$, high 4.96$
Factors to consider:
- Total employees count: 6 (+20.0%) as of 2023
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Liquidity and credit risks, Economic downturns and volatility, Third-party risks, Cybersecurity threats, Labor/talent shortage/retention
- Earnings for 18 months up through Q2 (+1 year) exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [5.24$, 14.81$]
- 2024-12-30 to 2025-12-30 estimated range: [3.59$, 10.69$]
Financial Metrics affecting the ANVS estimates:
- Negative: with PPE of -3.0 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -30.13 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 0 > -0.66
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: Shareholder equity ratio, % of -75.93 <= 18.93
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term ANVS quotes
Long-term ANVS plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $14.54MM | $25.51MM | $45.04MM |
| Operating Income | $-14.54MM | $-25.51MM | $-45.04MM |
| Non-Operating Income | $0.05MM | $0.18MM | $-11.17MM |
| R&D Expense | $8.48MM | $16.52MM | $38.79MM |
| Income(Loss) | $-14.49MM | $-25.33MM | $-56.20MM |
| Profit(Loss)* | $-14.49MM | $-25.33MM | $-56.20MM |
| Stockholders Equity | $44.49MM | $28.32MM | $-7.75MM |
| Assets | $46.00MM | $36.02MM | $10.21MM |
| Operating Cash Flow | $-9.13MM | $-17.31MM | $-39.97MM |
| Financing Cash Flow | $46.74MM | $0.00MM | $17.34MM |
| Earnings Per Share** | $-1.90 | $-3.10 | $-6.23 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.